The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

Giorgio Bedogni1, Stefano Bellentani2, Lucia Miglioli2, Flora Masutti1, Marilena Passalacqua2, Anna Castiglione1 and Claudio Tiribelli*1

Address: 1Centro Studi Fegato (Liver Research Center), AREA Science Park, Basovizza, Trieste, and Department of Biochemistry, Biophysics and Macromolecular Chemistry, University of Trieste, Trieste, Italy and 2Nutrition and Liver Center, AUSL Modena, Carpi Hospital, Carpi, Modena, Italy

Email: Giorgio Bedogni - giorgiobedogni@libero.it; Stefano Bellentani - liversb@unimore.it; Lucia Miglioli - monti73@cheapnet.it; Flora Masutti - f.masutti@csf.units.it; Marilena Passalacqua - passalacqua.marilena@libero.it; Anna Castiglione - acastiglione@univ.trieste.it; Claudio Tiribelli* - ctliver@csf.units.it

* Corresponding author

Abstract

Background: Fatty liver (FL) is the most frequent liver disease in Western countries. We used data from the Dionysos Nutrition & Liver Study to develop a simple algorithm for the prediction of FL in the general population.

Methods: 216 subjects with and 280 without suspected liver disease were studied. FL was diagnosed by ultrasonography and alcohol intake was assessed using a 7-day diary. Bootstrapped stepwise logistic regression was used to identify potential predictors of FL among 13 variables of interest [gender, age, ethanol intake, alanine transaminase, aspartate transaminase, gamma-glutamyl-transferase (GGT), body mass index (BMI), waist circumference, sum of 4 skinfolds, glucose, insulin, triglycerides, and cholesterol]. Potential predictors were entered into stepwise logistic regression models with the aim of obtaining the most simple and accurate algorithm for the prediction of FL.

Results: An algorithm based on BMI, waist circumference, triglycerides and GGT had an accuracy of 0.84 (95%CI 0.81–0.87) in detecting FL. We used this algorithm to develop the “fatty liver index” (FLI), which varies between 0 and 100. A FLI < 30 (negative likelihood ratio = 0.2) rules out and a FLI ≥ 60 (positive likelihood ratio = 4.3) rules in fatty liver.

Conclusion: FLI is simple to obtain and may help physicians select subjects for liver ultrasonography and intensified lifestyle counseling, and researchers to select patients for epidemiologic studies. Validation of FLI in external populations is needed before it can be employed for these purposes.
Background

Fatty liver (FL) is the most frequent liver disease in Western countries [1-4]. Obesity and its complications, especially type 2 diabetes and hypertriglyceridemia, are likely to be the main responsible of the current epidemic of FL, while ethanol intake may play a minor role [5-7]. In a nested case-control study of the Dionysos Project, we found that body mass index (BMI) was a stronger risk factor for FL than ethanol intake in the general population of Northern Italy [6]. Interestingly, this finding was confirmed by a recent study performed in China [8]. Waist circumference has long been hypothesized to be a predictor of FL independently from BMI, but data for the general population were not available until very recently [1,8]. Because BMI is a surrogate index of body adiposity [9], direct indexes of adiposity such as skinfolds can be of value when studying the relationship between body fatness per se and disease [10,11]. Hyperinsulinemia and insulin resistance are common in subjects with FL independently from BMI and thus are expected to be markers of FL in the general population [12]. Despite the operational separation of FL into alcoholic and non-alcoholic fatty liver disease (NAFLD) [4], the relative contribution of ethanol intake and other factors in the pathogenesis of FL is still uncertain [3]. Using data collected during the Dionysos Nutrition & Liver Study [1], we evaluated the contribution of ethanol intake, anthropometry, liver enzymes and metabolic parameters to the risk of FL and developed an algorithm for the prediction of FL in the general population.

Methods

Study design

The protocol of the Dionysos Nutrition & Liver Study was described in detail elsewhere [1]. Briefly, of 5780 residents of Campogalliano (Modena, Italy) aged 18 to 75 years, 3345 (58%) agreed to participate to the study; 3329 (99%) of them had all the data required by the Dionysos Project [7,13] and were considered for further analysis. 497 (15%) of them had suspected liver disease (SLD) according to at least one of the following criteria: 1) alanine transaminase (ALT) > 30 U*L^{-1}; 2) gamma-glutamyl-transferase (GGT) > 35 U*L^{-1}; 3) presence of hepatitis B surface antigen (HBsAg); 4) presence of Hepatitis C (HCV) virus ribonucleic acid (RNA) after detection of anti-HCV antibodies. The 497 subjects with SLD were matched with an equal number of subjects of the same age and sex but without SLD, randomly selected among the remaining 2832 subjects. After exclusion of subjects with HBV or HCV infection, the original analysis was performed on 224 subjects with and 287 without SLD [1]. The present analysis is performed on 216 (96%) subjects with and 280 (97%) without SLD, based on the availability of skinfold measurements.

Statistical analysis

Continuous variables are given as medians and interquartile ranges (IQR) because of skewed distributions. Comparisons of continuous variables between subjects with and without FL were performed with the Mann-Whitney test and those of nominal variables with the Fisher’s exact test. To identify candidate predictors of FL, we performed a stepwise logistic regression analysis on 1000 bootstrap samples of 496 subjects (probability to enter = 0.05 and probability to remove = 0.1) [21]. All variables besides gender were evaluated as continuous predictors. Linearity of logits was ascertained using the Box-Tidwell procedure [22]. To obtain a linear logit, we transformed age using the coefficient suggested by the Box-Tidwell procedure [(age/10) ∧ 4.9255] and ALT, AST, GGT, insulin and triglycerides using natural logarithms (log.). The logits of the other predictors (BMI, waist circumference, glucose, cholesterol, ethanol and the sum of 4 skinfolds) were linear.
Candidate predictors identified at bootstrap analysis were evaluated using three stepwise logistic models before obtaining a final prediction model (probability to enter = 0.01 and probability to remove = 0.02; these more stringent levels were used to protect against type I errors). The goodness of fit of the models was evaluated using the Hosmer-Lemeshow statistic and their accuracy was assessed by calculating the non-parametric area (AUC) under the receiver-operating curve (ROC) with 95% confidence intervals (95%CI) [23,24]. The standard errors of the regression coefficients of the final model were calculated using 1000 bootstrap samples of 496 subjects. The probabilities obtained from the final model were multiplied by 100 to obtain the fatty liver index (FLI). The sensitivity (SN), specificity (SP), positive likelihood ratio (LR+) and negative likelihood ratio (LR-) of 10-value intervals of FLI were calculated [23]. Statistical analysis was performed using STATA 9.2 (StataCorp, College Station, Texas, USA).

Results

Table 1 gives the characteristics of the subjects with and without FL. FL was more frequent among males than females (54 vs. 34%). Age, ethanol intake and cholesterol did not differ between subjects with and without FL. On the contrary, ALT, AST, GGT, BMI, waist circumference, the sum of 4 skinfolds, glucose, insulin and triglycerides were significantly higher in subjects with than in those without FL.

Figure 1 (Model 1) gives the number of times each of the 13 variables of interest was selected by bootstrapped stepwise logistic regression. The predictors identified most frequently were insulin (93%), triglycerides (91%), BMI (78%), gender (77%), GGT (77%) and age (64%). When these 6 predictors were entered into the stepwise model, age did not remain in the model ($p = 0.0766$; model not shown). The model based on the remaining 5 predictors fitted well ($p = 0.9976$, Hosmer-Lemeshow statistic) and had a ROC-AUC of 0.85 (95%CI 0.82–0.89; model not shown).

Since insulin is not routinely measured, we tested whether its removal from the model would decrease the accuracy of the estimate. After exclusion of insulin, the predictors most frequently identified were triglycerides (100%), GGT (80%), BMI (79%), ALT (70%), the sum of 4 skinfolds (68%) and gender (67%) (Figure 1, Model 2). When these 6 predictors were entered into the stepwise model, ALT did not enter it ($p = 0.0780$; model not shown). The model based on the 5 remaining predictors fitted well ($p = 0.9704$, Hosmer-Lemeshow statistic) and had a ROC-AUC of 0.85 (95%CI 0.81–0.88; model not shown).

Since skinfolds are not routinely measured, we tested whether their removal from the model would decrease the accuracy of the estimate. After exclusion of the sum of 4 skinfolds, the predictors identified most frequently were triglycerides (100%), BMI (95%), ALT (77%), GGT (73%) and waist circumference (58%) (Figure 1, Model 3). When these 5 predictors were entered into the stepwise model, ALT did not enter it ($p = 0.0241$; $p$ to remove = 0.0200; model not shown). The model based on the remaining 4 predictors fitted well ($p = 0.9704$, Hosmer-Lemeshow statistic) and had a ROC-AUC of 0.85 (95%CI 0.81–0.88; model not shown).

A comparison of the ROC-AUCs of Models 2 ($p = 0.6320$; Bonferroni’s correction) and 3 ($p = 0.1038$) vs. Model 1 revealed no difference so that we choose Model 3 for further analysis. The bootstrapped regression coefficients of Model 3 are given in Table 2. We multiplied the probabil-

| Table 1: Measurements of subjects with and without fatty liver. |
|---------------------------------------------------------------|
| **FL (n = 228)** | **No FL (n = 268)** | **p** |
| Gender (male/female, n) | 164/64 | 141/127 | <0.0001 |
| Age (years) | 58 (17) | 57 (26) | 0.9535 |
| Ethanol (g·day⁻¹) | 13 (35) | 11 (28) | 0.1272 |
| ALT (U·L⁻¹) | 27 (21) | 19 (16) | <0.0001 |
| AST (U·L⁻¹) | 22 (10) | 20 (8) | 0.0004 |
| GGT (U·L⁻¹) | 31 (35) | 19 (14) | <0.0001 |
| BMI (kg·m⁻²) | 29.5 (5.8) | 25.7 (4.1) | <0.0001 |
| Waist circumference (cm) | 98 (16) | 86 (14) | <0.0001 |
| Sum of 4 skinfolds (mm) | 74.1 (37.4) | 59.6 (26.8) | <0.0001 |
| Glucose (mg·dL⁻¹) | 96 (18) | 89 (13) | <0.0001 |
| Insulin (mU·L⁻¹) | 9 (8) | 5 (4) | <0.0001 |
| Triglycerides (mg·dL⁻¹) | 141 (102) | 91 (60) | <0.0001 |
| Cholesterol (mg·dL⁻¹) | 219 (57) | 212 (52) | 0.1547 |

Values are medians and interquartile ranges for continuous variables and number of subjects for categorical variables.

Abbreviations: FL = fatty liver; $p$ = p-value (Mann-Whitney U-test for continuous variables and Fisher’s Exact test for categorical variables); ALT = alanine transaminase; AST = aspartate transaminase; GGT = gamma-glutamyl-transferase; BMI = body mass index.
Table 2: The parameters of the fatty liver index (FLI).

| Predictor                                | β    | SE (β) | STD (β) | p     |
|------------------------------------------|------|--------|---------|-------|
| Loge (triglycerides, mg*dL⁻¹)            | 0.953| 0.211  | 0.308   | <0.0001|
| BMI (kg*m²⁻¹)                            | 0.139| 0.050  | 0.353   | 0.006 |
| Loge (GGT, U*L⁻¹)                        | 0.718| 0.202  | 0.278   | <0.0001|
| Waist circumference (cm)                 | 0.053| 0.019  | 0.356   | 0.005 |
| Constant                                 | -15.745| 1.631 | -       | <0.0001|

Abbreviations: β = regression coefficient; SE = standard error; STD = standardized value; loge = natural logarithm. Other abbreviations as in Table 1. FLI is calculated by multiplying the predicted probabilities per 100 (see text for the formula).

Figure 1
Selection of candidate predictors at bootstrapped stepwise logistic regression. Bars indicate the number of times out of 1000 that the variables were selected for inclusion in 3 models. Model 1 is the starting model, Model 2 removes insulin and Model 3 removes skinfolds. Data are sorted using Model 3. Abbreviations: * = transformed using natural logarithm; ** = transformed using Box-Tidwell transformation (see text for details); other abbreviations as in Table 1.
ities generated by Model 3 per 100 to obtain a score comprised between 0 and 100, which we call the “fatty liver index” (FLI). FLI is thus calculated as:

$$FLI = \left( e^{0.953 \times \log (\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log (\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745} \right) / \left( 1 + e^{0.953 \times \log (\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log (\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745} \right) \times 100$$

As shown by the standardized regression coefficients, the greatest contribution to the prediction of FL came from waist circumference, followed by BMI, triglycerides and GGT. Table 3 gives the SN, SP, LR+ and LR- for 10-unit intervals of FLI. A FLI < 30 can be used to rule out (SN = 87%; LR- = 0.2) and a FLI ≥ 30 to rule in hepatic steatosis (SP = 86%; LR+ = 4.3).

### Discussion

We used data from the Dionysos Nutrition & Liver Study to develop a simple algorithm for the prediction of FL. Age was not associated with FL in any of the multivariable models while gender lost its association with FL after exclusion of insulin and skinfolds. Ethanol intake was not associated with FL in any of the models. Thus, at least at the values of intake observed in the Dionysos Nutrition & Liver Study, ethanol is not a risk factor for FL in the general population of Northern Italy.

Waist circumference and BMI were the strongest predictors of FL in the final model. Together with the lack of association of FL with ethanol intake, this finding strongly supports the hypothesis that obesity is the main responsible of the current epidemic of FL [1,4,6]. It is of some interest that waist circumference did not add to the prediction of FL when skinfolds were in the model but from a practical viewpoint, there is no need to measure skinfolds for predicting FL.

Among liver enzymes, only GGT was an independent predictor of FL while AST was not associated with FL in any of the models and ALT was not an independent predictor of FL. We have previously shown that ALT is not a surrogate marker of NAFLD and the present study extends this consideration to the entire spectrum of FL disease [1].

Insulin was the predictor most frequently selected for inclusion in Model 1 and was the second most important predictor after BMI in the same model (data not shown). Thus, we confirm that insulin is an independent risk factor for FL in the general population [12]. It is of some interest that waist circumference did not add to the prediction of FL when insulin was in the model but that it was the strongest predictor of FL in the final model. This cannot be easily explained by the known association between waist and insulin (resistance) because BMI is similarly correlated with this latter [25,26] as also observed in this study (data not shown). Triglycerides were independent predictors of FL in all models, confirming our previous findings [16]. Glucose and cholesterol were not predictors of FL even if it may be noticed that the selection of glucose as potential predictor increased after exclusion of insulin from the model.

The main limitations of the Dionysos Nutrition & Liver Study are the suboptimal respondent rate (58%) and the fact that ultrasonography cannot detect steatohepatitis (SH) [1]. This latter diagnosis can be obtained only by biopsy and, because of obvious ethical reasons, a SH score will never be available in a representative sample of the general population [3]. Scores developed in clinical series may be used for this purpose but they have not been tested in the general population [27,28].

### Conclusion

The “fatty Liver index” (FLI) we developed is accurate and easy to employ as BMI, waist circumference, triglycerides and GGT are routine measurements in clinical practice [7,29,30]. In our population, a FLI < 30 ruled out and a FLI ≥ 60 ruled in hepatic steatosis as detected by ultrasonography. Potential clinical uses of FLI include the selection of subjects to be referred for ultrasonography and the identification of patients for intensified lifestyle counseling [30,31]. On the research side, FLI may be used to select subjects at greater risk of FL for planning observational or interventional studies [30,32]. Even though, for reasons of biological plausibility and coherence with previous studies [5,6,8], we expect that the parameters employed by FLI will be predictors of FL in Western countries besides Italy, it is very important that FLI be validated in external populations before it is employed in practice.

### Table 3: Diagnostic accuracy of the fatty liver index.

| FLI cut-point | % | SN | SP | LR+ | LR- |
|---------------|---|----|----|-----|-----|
| ≥10           | 90| 98 | 17 | 1.2 | 0.1 |
| ≥20           | 74| 94 | 44 | 1.7 | 0.1 |
| ≥30           | 60| 87 | 64 | 2.4 | 0.2 |
| ≥40           | 53| 82 | 72 | 2.9 | 0.3 |
| ≥50           | 43| 70 | 80 | 3.5 | 0.4 |
| ≥60           | 36| 61 | 86 | 4.3 | 0.5 |
| ≥70           | 28| 49 | 91 | 5.2 | 0.6 |
| ≥80           | 18| 35 | 96 | 9.3 | 0.7 |
| ≥90           | 9 | 18 | 99 | 15.6| 0.8 |

Abbreviations: FLI = fatty liver index; % = number of patients with FLI ≥ cut-point; SN = sensitivity; SP = specificity; LR+ = positive likelihood ratio; LR- = negative likelihood ratio.
Abbreviations
7DD = 7-day diary
95%CI = 95% confidence intervals
ALT = Alanine transaminase
Anti-HCV = Antibodies against hepatitis C virus
AST = Aspartate transaminase
AUC = Area under the curve
BMI = Body mass index
FL = Fatty liver
FLI = Fatty liver index
GGT = Gamma-glutamyl-transferase
HbsAg = Hepatitis B surface antigen
HBV = Hepatitis B virus
HCV = Hepatitis C virus
HCV-RNA = Hepatitis C ribonucleic acid
IQR = Interquartile range
LR+ = Positive likelihood ratio
LR- = Negative likelihood ratio
NAFLD = Non-alcoholic fatty liver disease
ROC = Receiver-operating curve
SH = Steatohepatitis
SN = Sensitivity
SP = Specificity
SLD = Suspected liver disease

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GB co-designed the Dionysos Nutrition & Liver Study, analyzed the data and wrote the manuscript; SB and CT co-designed the Dionysos Nutrition & Liver Study and contributed to the manuscript; LM, FM and AC performed the medical evaluation of subjects; MP performed the nutritional assessment of subjects. All authors read and approved the manuscript.

Acknowledgements
The Dionysos Nutrition & Liver Study was supported by grants from Fondazione Cassa di Risparmio di Modena, Fondazione Cassa di Risparmio di Gorizia, Banca Popolare dell’Emilia Romagna, Comune di Campogalliano, Azienda USL di Modena, Assessorato alla Sanità della Regione Emilia Romagna, Assessorato alla Sanità della Regione Friuli Venezia Giulia, and Fondo per lo Studio delle Malattie del Fegato-ONLUS.

References
1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
2. Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004, 16:1087-1093.
3. Bedogni G, Bellentani S: Fatty liver: how frequent is it and why? Ann Hepatol 2004, 3:63-65.
4. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
5. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
6. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
7. Bellentani S, Tiribelli C: The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001, 35:531-537.
8. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY: Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005, 43:508-514.
9. Bedogni G, Pietrobelli A, Heymsfield SB, Borghi A, Manzieri AM, Morini P, Battistini N, Salvadori G: Is body mass index a measure of adiposity in elderly women? Obes Res 2001, 9:17-20.
10. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K: Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005, 330:1360.
11. Twisk JW, Kemper HC, van Mechelen W, Post GB, van Lenthe FJ: Body fatness: longitudinal relationship of body mass index and the sum of skinfolds with other risk factors for coronary heart disease. Int J Obes Relat Metab Disord 1998, 22:915-922.
12. Bugianesi E, McCullough AJ, Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
13. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristanini G: Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994, 20:1442-1449.
14. Bellentani S, Pozzato G, Saccoccio G, Crovato M, Crocè LS, Mazzoran L, Masutti F, Cristanini G, Tiribelli C: Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999, 44:874-880.
15. Lohman , Roche , Martorell : Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books: 1988.
16. Durnin JV, Womersley J: Total body fat, calculated from body density, and its relationship to skinfold thickness in 571 people aged 12–72 years. Proc Nutr Soc 1973, 32:45A.
17. Fiori G, Facchini F, Pettener D, Rimondi A, Battistini N, Bedogni G: Relationships between blood pressure, anthropometric characteristics and blood lipids in high- and low-altitude populations from Central Asia. Ann Hum Biol 2000, 27:19-28.
18. Thompson FE, Byers T: Dietary assessment resource manual. J Nutr 1994, 124:2245S-2317S.
19. Willett W: *Nutritional epidemiology* New York: Oxford University Press; 1998.
20. MacDonald I: *Health issues related to alcohol consumption* ILSI Press; 1993.
21. Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: *Internal validation of predictive models: efficiency of some procedures for logistic regression analysis*. *J Clin Epidemiol* 2001, 54:774-781.
22. Box GEP, Tidwell PW: *Transformation of the Independent Variables*. *Technometrics* 1962, 4:531-550.
23. Zhou , Obuchowski , McClish : *Statistical methods in diagnostic medicine* New York: Wiley; 2002.
24. Hosmer DW, Lemeshow S: *Applied logistic regression* New York: Wiley; 2000.
25. Farin HM, Abbasi F, Reaven GM: *Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake*. *Metabolism* 2005, 54:1323-1328.
26. Reaven GM: *The metabolic syndrome: is this diagnosis necessary?* *Am J Clin Nutr* 2006, 83:1237-1247.
27. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T, LIDO Study Group, CYTOL study group: *Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease*. *BMC Gastroenterol* 2006, 6:6.
28. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J: *The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis*. *Comp Hepatol* 2005, 4:10.
29. Kushner RF, Bhatner DJ: *Risk assessment of the overweight and obese patient*. *J Am Diet Assoc* 2005, 105:553-562.
30. Bayard M, Holt J, Boroush E: *Nonalcoholic fatty liver disease*. *Am Fam Physician* 2006, 73:1961-1968.
31. Marchesini G, Natale S, Manini R, Agostini F: *Review article: the treatment of fatty liver disease associated with the metabolic syndrome*. *Aliment Pharmacol Ther* 2005, 22(Suppl 2):37-39.
32. Comar KM, Sterling RK: *Review article: Drug therapy for non-alcoholic fatty liver disease*. *Aliment Pharmacol Ther* 2006, 23:207-215.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-230X/6/33/prepub